Abivax SA (FR:ABVX) has released an update.
Abivax, a clinical-stage biotech company, has disclosed its share capital and voting rights structure, reporting a total of 63,276,925 shares and 70,557,851 theoretical voting rights. The company, which focuses on developing treatments for chronic inflammatory diseases, has also noted that the number of exercisable voting rights stands at 70,556,237.
For further insights into FR:ABVX stock, check out TipRanks’ Stock Analysis page.
